PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today that it has filed a preliminary short form prospectus (the “Preliminary Prospectus”) with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with an offering (the “Offering”) of common shares of the Company (“Common Shares”) and/or pre-funded common share purchase warrants of the Company (“Pre-Funded Warrants” and, together with the Common Shares, the “Securities”) in lieu of Common Shares. The Offering is expected to be completed on a commercially reasonable efforts agency basis pursuant to an agency agreement to be entered into between the Company and Bloom Burton Securities Inc. (“Bloom Burton” or the “Agent”). The number of Securities to be distributed, the size of the Offering and the price of each Common Share and Pre-Funded Warrant will be determined by negotiation between the Company and Bloom Burton in the context of the market with final terms to be determined at the time of pricing. The Company intends to use the net proceeds from the Offering to obtain US FDA 510(k) clearance of the next generation Novasight Hybrid system, as well as complete a limited market release and initiate a broader commercial launch in the United States. The Company also intends to use the net proceeds for working capital and other general corporate purposes. The Offering is expected to close on or about December 12, 2025 (the “Closing Date”) or such later date as may be agreed upon by the Company and Bloom Burton. The Offering is subject to the Company and the Agent entering into a definitive agency agreement, and subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the TSX Venture Exchange (“TSXV”). In addition, the Securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws. For further details with respect to the Offering, please see the Preliminary Prospectus, a copy of which is available on SEDAR+ at www.sedarplus.ca. This press release is not an offer to sell or the solicitation of an offer to buy the Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The Securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and such securities may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons absent registration or an applicable exemption from U.S. registration requirements. “United States” and “U.S. persons” have the meanings ascribed to them in Regulation S under the U.S. Securities Act. Access to the Preliminary Prospectus and any amendments to such document will be provided in accordance with securities legislation relating to procedures for providing access to a short form prospectus and any amendment thereto. The Preliminary Prospectus is accessible on SEDAR+ at www.sedarplus.ca. Alternatively, an electronic or paper copy of the Preliminary Prospectus and any amendment to such document may be obtained without charge, from the Agent by email at ECM@bloomburton.com, by telephone at 416-640-7585 or by providing the contact with an email address or address, as applicable. The Preliminary Prospectus contains important, detailed information about the Company and the Offering. Prospective investors should read the Preliminary Prospectus before making an investment decision. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid™ System has regulatory clearance in the U.S., Canada, China, and Japan. For more information, visit conavi.com. CONTACT: Christina CameronIR@conavi.com Notice on forward-looking statements: This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the anticipated terms and jurisdictions of the Offering; securities offered thereunder; the timing of the Offering, including the anticipated Closing Date; use of proceeds from the Offering; regulatory and exchange approvals, including the listing of the Common Shares offered pursuant to the Offering on the TSXV. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the Preliminary Prospectus and the “Risk Factors” sections of the joint information circular of the Company dated August 30, 2024 (both of which are on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. 535335320v.6

– Mark Quick Appointed Chief Financial Officer, Bringing Extensive Public Company Capital Markets Expertise — Current CFO, Stefano Picone, will take on a Transitional Strategic Role to Support Leadership Continuity During Growth Phase — Leadership additions follow submission of next-generation Novasight™ to the FDA for 510(k) clearance -TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Conavi Medical  (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced strategic leadership changes aligned to the Company’s planned commercial launch and expansion in the United States.Conavi has submitted its next generation Novasight Hybrid IVUS/OCT intravascular imaging system to the U.S. Food and Drug Administration (FDA) for 510(k) clearance, and is actively building the infrastructure required to support a successful U.S. launch in the largest market for intravascular imaging globally.As part of these preparations, Conavi has appointed Mark Quick as Chief Financial Officer, bringing strong capital-markets expertise from senior roles at publicly traded life sciences and medtech companies. He will oversee financial strategy and investor engagement as Conavi prepares for launch in the United States.Stefano Picone will take on a transitional strategic role with the Company as the Chief Strategy Officer. Having successfully guided Conavi through its go-public transaction, first public equity financing, and organizational scale-up, Mr. Picone now shifts focus to strategic execution and ensuring continuity as the Company advances through this commercial scale-up period.“We are entering a very exciting chapter for Conavi as we prepare for broader U.S. adoption of our hybrid imaging platform,” said Thomas Looby, Chief Executive Officer of Conavi Medical. “Mark brings the ideal financial and strategic mindset to help guide our U.S. launch and expand our presence in the capital markets. Stefano’s leadership over the past decade has been instrumental in establishing the corporate foundation we stand on today, and we are grateful for his significant financial stewardship and continued support as we execute on Conavi’s long-term growth and value-creation strategy. With these leadership enhancements and U.S. expansion activities advancing, we are confident we have the right team, capabilities, and focus in place to deliver success in the United States and create long-term value for shareholders.”“Conavi has a differentiated and highly compelling technology platform,” said Mark Quick, Chief Financial Officer of Conavi Medical. “I’m excited to join at this stage of growth and look forward to working with the team to advance a strong financial, operational, and capital markets strategy as the Company prepares for commercialization.”Mark Quick — Chief Financial OfficerMr. Quick is a seasoned finance executive with more than 20 years of experience in the medical technology and life sciences sectors. Prior to joining Conavi, he held senior financial leadership roles with publicly traded companies on Nasdaq, where he led capital markets strategy, budgeting and forecasting, financial reporting, and corporate development initiatives. Earlier in his career, Mr. Quick served as a sell-side equity research analyst at Canaccord Genuity, where he covered the medical device industry. Mr. Quick holds a Bachelor of Science in Mechanical Engineering from the University of Massachusetts, Amherst, and an International Master of Business Administration from the University of South Carolina.About Conavi MedicalConavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid™ System has regulatory clearance in the U.S., Canada, China, and Japan. For more information, visit conavi.com.Cautionary Statement Regarding Forward-Looking InformationThis news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to transitions in the Company’s strategic leadership, Conavi’s plans for the commercialization of its Novasight Hybrid™ System and expected FDA clearance and the commercial launch of next generation Novasight in the U.S. and other U.S. expansion activities.These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi’s ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the “Risk Factors” sections of the joint information circular of Conavi dated August 30, 2024 and in the final short form prospectus of Conavi dated April 15, 2025 (each of which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.Contact:Investors: Christina Cameron, IR@conavi.com

Agreement to provide up to $2.5 million CAD to Conavi Medical to support the commercial launch of the next-generation Novasight Hybrid systemTORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, is pleased to announce that it has entered into an agreement with the Province of Ontario as part of the Life Sciences Scale-Up Fund (LSSUF). LSSUF provides financial support to help small-to-medium sized enterprises based in Ontario to scale up the life sciences sector. As part of the agreement, Conavi is eligible to receive up to $2.5 million CAD over the course of the project to cover up to one-third of eligible project costs related to the commercial launch of the next-generation Novasight Hybrid™ system, subject to certain requirements. Additional details regarding LSSUF can be found at https://www.ontario.ca/page/life-sciences-scale-fund. “We are incredibly grateful to the Province of Ontario, the Ministry of Economic Development, Job Creation, and Trade, and Minister Victor Fedeli for the ongoing support of Conavi and our vision,” said Tom Looby, Chief Executive Officer of Conavi Medical. “Heart disease remains a leading cause of death in Canada and globally, and intravascular imaging has been shown to significantly improve outcomes for patients undergoing coronary procedures. We believe the next-generation Novasight Hybrid™ system is well positioned to become a category leader and help propel the Ontario ecosystem.” “Ontario’s Life Sciences Scale-Up Fund is accelerating the development of next-generation health technologies and reinforcing our province’s position as a global leader in life science innovation,” said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. “Through this partnership, Conavi Medical will advance the design and manufacturing of their cardiovascular imaging technology, ensuring more medical breakthroughs are developed right here, in Ontario.” Conavi’s proprietary Novasight Hybrid™ system uniquely combines both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single integrated system. This dual-modality approach is designed to provide cardiologists with a comprehensive view of coronary arteries, potentially enabling more precise diagnosis and treatment of cardiovascular disease. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid™ System has regulatory clearance in the U.S., Canada, China, and Japan. For more information, visit conavi.com. Cautionary Statement Regarding Forward-Looking Information This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to Conavi’s actual receipt of funds from the Province of Ontario under the LSSUF program and satisfaction of the conditions thereto, Conavi’s plans for the commercialization of its Novasight Hybrid™ System and expected FDA clearance and the commercial launch of next generation Novasight in the U.S. These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi’s ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the “Risk Factors” sections of the joint information circular of Conavi dated August 30, 2024 and in the final short form prospectus of Conavi dated April 15, 2025 (each of which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contact:Stefano PiconeChief Financial Officer(416) 483-0100

US FDA 510(k) submission remains on track for calendar Q3 2025Successful validation testing of Novasight Hybrid™ system with key opinion leaders Recent academic publications underscore importance of intravascular imaging and potential of hybrid IVUS / OCT$20 million financing completed in April strengthens balance sheet and supports anticipated U.S. launch TORONTO, Aug. 29, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced its financial results for the fiscal quarter ended June 30, 2025. “Fiscal Q3 was an important quarter as we completed validation testing with leading interventional cardiologists, giving us confidence that our next generation Novasight™ is designed to be a best-in-class product,” said Thomas Looby, CEO of Conavi Medical. “We remain on track to submit our 510(k) application to the U.S. FDA in calendar Q3 2025, a key milestone that positions us for an anticipated U.S. launch in the first half of calendar 2026. Importantly, the $20 million financing completed in April strengthens our position as we work towards these key milestones.” A recent publication in the Journal of the American College of Cardiology (JACC) underscores the rising importance of intravascular imaging in the treatment of patients with complex coronary artery disease, a market that continues to grow as physicians increasingly rely on imaging to guide better outcomes. Combined with hands-on validation by experts using our system, these developments highlight the strong clinical and commercial momentum behind our hybrid IVUS / OCT technology and its potential to transform patient care. Business Highlights: Successful Validation Testing with Key Opinion Leaders: In July 2025, Conavi conducted two pre-clinical animal experiments with several leading interventional cardiologists, confirming that next generation Novasight meets key customer specifications for usability, imaging performance, and workflow integration. These studies validated market readiness and established that the system is competitive with best-in-class stand-alone IVUS and OCT solutions. 510(k) Regulatory Submission Remains on Track: The Company remains on track to submit its 510(k) application to the U.S. FDA in Q3 of calendar 2025, a critical milestone toward its planned U.S. launch in H1 calendar 2026. Transfer to Production Underway: Conavi advanced preparations to transition next generation Novasight from development to manufacturing. Transfer to production is expected to be completed to coincide with the planned U.S. launch in H1 calendar 2026. Peer-Reviewed JSCAI Publication: In July 2025, Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) published a case study with images from the first-generation Novasight system highlighting hybrid IVUS / OCT imaging as a breakthrough modality for guiding complex coronary interventions, further validating Conavi’s unique clinical approach. $20 Million Financing Strengthens Balance Sheet: In April 2025, Conavi completed an upsized equity offering for gross proceeds of $20 million. Led by U.S. institutional investors, the financing provides resources to complete the regulatory submission, advance transfer to production, and prepare for anticipated U.S. commercial launch of Novasight. Upcoming Targeted Milestones (calendar dates): Q3 2025 Planned submission of next generation Novasight U.S. FDA 510(k) application. Q4 2025 Publish additional whitepapers and case studies to drive awareness. H1 2026 Expected FDA clearance and U.S. commercial launch of next generation Novasight. Fiscal Q3 2025 Financial Results All amounts are in Canadian dollars unless specified otherwise: As previously reported, in the two preceding fiscal years and in FY Q2 2025, the Company focused on development of the next-generation Novasight system and on incorporating clinical user feedback from its earlier Novasight system. This focus and shift in resources continued into FY Q3 2025. For the quarter ended June 30, 2025, the Company recorded revenue of $63,000 compared to $401,000 for the same period in the prior year. Operating expenses for the three months ended June 30, 2025, were $4.7 million, compared to $8.8 million for the same period in the prior year. The operating loss for Q3 FY 2025 was $4.6 million, compared to $8.9 million for Q3 FY 2024.   This drop largely stems from a reduction in research & development expenses, which were $3.2 million in FY Q3 2025, compared to $6.3 million in the same period in FY 2024, reflecting a reduction in costs as the next-generation system nears FDA submission.   The Q3 FY 2025 net loss was $3.6 million, or $0.05 per common share, compared to a net loss of $13.0 million, or $2.12 per common share, in the three-month period ended June 30, 2024. The net loss in Q3 2025 was principally due to operating costs, partially offset by a gain in the fair value of warrant liability; the loss in Q3 FY 2024 was principally due to operating costs. In both periods, the majority of operating costs were attributable to research & development activities. As of June 30, 2025, cash and cash equivalents were $11.3 million, up from $0.4 million as of September 30, 2024. For detailed financial results, please refer to Conavi Medical’s filings on SEDAR+ and the Company’s website www.conavi.com. Additional Disclosure Regarding $20M Public Offering Further to the Company’s press release dated April 23, 2025 regarding the closing of its public equity offering for aggregate gross proceeds of $20 million (the “Offering”), the Company confirms that in connection with the Offering, it paid a cash commission of $1,034,657.75 and issued 2,408,350 compensation options to Bloom Burton Securities Inc., the sole and exclusive agent for the Offering. In addition, in connection with the Offering, 77,700 and 35,000 compensation options were issued to Raymond James Ltd. and Research Capital Corporation, respectively. About Conavi MedicalConavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid™ System has regulatory clearance in the U.S., Canada, China, and Japan. For more information, visit conavi.com. Cautionary Statement Regarding Forward-Looking Information This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to Conavi’s plans for the commercialization of its Novasight Hybrid™ System and expected FDA clearance and the commercial launch of next generation Novasight in the U.S. These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi’s ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the “Risk Factors” sections of the joint information circular of Conavi dated August 30, 2024 and in the final short form prospectus of Conavi dated April 15, 2025 (each of which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contact:Stefano PiconeChief Financial Officer(416) 483-0100

TORONTO, June 03, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), announced that its board of directors (the “Board”) has approved grants of stock options (the “Stock Options”) Plan on June 2, 2025 pursuant to the terms of its Omnibus Equity Incentive Plan. A total of 5,849,098 Stock Options have been awarded to directors, officers, employees and consultants of the Company. The Stock Options are exercisable at a price of $0.39 CAD per share (being the closing price of the Company’s shares on the TSXV on June 2, 2025) for a period of 10 years from the date of the grant. 1,930,172 of such Stock Options were allocated as follows to the Company’s independent directors: 341,624 Stock Options to Anthony Giovinazzo, 341,624 Stock Options to Cathy Steiner, 330,807 Stock Options to Robert Mitchell, 358,242 Stock Options to Susan Allen and 557,875 Stock Options to Aaron Davidson. 3,581,216 of such Stock Options were allocated as follows to the Company’s officers: 298,413 Stock Options to Travis More, 266,863 Stock Options to Amandeep Thind, 393,924 Stock Options to Sumeet Dham, 425,000 Stock Options to Stefano Picone and 2,197,646 Stock Options to Thomas Looby. The remaining Stock Options were granted to other employees and consultants. The Company also announced minor changes to the composition of its Audit Committee, with Board Chair Aaron Davidson having stepped down from the Audit Committee and independent directors Susan Allen, Cathy Steiner and Robert Mitchell continuing to serve. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare. For more information, visit http://www.conavi.com/. Cautionary Statement Regarding Forward-Looking Information  This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to Conavi’s plans for the commercialization of its Novasight Hybrid™ System. These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi’s ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the “Risk Factors” sections of the joint information circular of Conavi dated August 30, 2024 and in the final short form prospectus of Conavi dated April 15, 2025 (each of which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contacts Stefano Picone Chief Financial Officer (416) 483-0100